Intellia Therapeutics, Inc.
NTLA
$12.35
$0.151.23%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -9.50% | 78.79% | 51.27% | 104.76% | -42.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -9.50% | 78.79% | 51.27% | 104.76% | -42.54% |
| Cost of Revenue | -25.54% | -26.12% | -27.69% | -19.81% | -3.06% |
| Gross Profit | 28.44% | 41.68% | 34.87% | 29.09% | -10.72% |
| SG&A Expenses | 20.12% | -3.15% | 3.59% | -4.08% | -6.70% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -15.90% | -18.48% | -18.60% | -14.90% | -3.85% |
| Operating Income | 16.78% | 27.66% | 23.00% | 20.89% | -5.97% |
| Income Before Tax | 15.83% | 25.69% | 25.34% | 31.11% | -6.42% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 15.83% | 25.69% | 25.34% | 31.11% | -6.42% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 15.83% | 25.69% | 25.34% | 31.11% | -6.42% |
| EBIT | 16.78% | 27.66% | 23.00% | 20.89% | -5.97% |
| EBITDA | 16.89% | 28.05% | 23.28% | 21.20% | -6.12% |
| EPS Basic | 26.48% | 34.71% | 31.56% | 35.60% | 1.81% |
| Normalized Basic EPS | 25.80% | 35.58% | 27.61% | 24.26% | -2.14% |
| EPS Diluted | 26.48% | 34.71% | 31.56% | 35.60% | 1.81% |
| Normalized Diluted EPS | 25.80% | 35.58% | 27.61% | 24.26% | -2.14% |
| Average Basic Shares Outstanding | 14.48% | 13.81% | 9.09% | 6.97% | 8.37% |
| Average Diluted Shares Outstanding | 14.48% | 13.81% | 9.09% | 6.97% | 8.37% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |